Eli Lilly’s Astute Ascendance: A Biopharma Bull on the Run
BofA Bullish Analysis Elevates Eli Lilly BofA Securities casts a luminous spotlight on Eli Lilly and Company (LLY), hailing it as a premier contender in the Biopharma arena. Surging with a stellar year-to-date growth of +29% (dwarfing the DRG index’s +10%), Eli Lilly beams brightly …